CN115605218B - 用于治疗大疱性表皮松解症的归巢肽引导的核心蛋白聚糖缀合物 - Google Patents

用于治疗大疱性表皮松解症的归巢肽引导的核心蛋白聚糖缀合物

Info

Publication number
CN115605218B
CN115605218B CN202180031725.5A CN202180031725A CN115605218B CN 115605218 B CN115605218 B CN 115605218B CN 202180031725 A CN202180031725 A CN 202180031725A CN 115605218 B CN115605218 B CN 115605218B
Authority
CN
China
Prior art keywords
leu
ser
pro
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180031725.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN115605218A (zh
Inventor
T·贾维恩
T·贝马瑞
U·梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tampere University Foundation SR
Original Assignee
Tampere University Foundation SR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tampere University Foundation SR filed Critical Tampere University Foundation SR
Publication of CN115605218A publication Critical patent/CN115605218A/zh
Application granted granted Critical
Publication of CN115605218B publication Critical patent/CN115605218B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202180031725.5A 2020-04-28 2021-04-28 用于治疗大疱性表皮松解症的归巢肽引导的核心蛋白聚糖缀合物 Active CN115605218B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063016359P 2020-04-28 2020-04-28
FI20205431 2020-04-28
US63/016,359 2020-04-28
FI20205431 2020-04-28
PCT/FI2021/050318 WO2021219940A1 (en) 2020-04-28 2021-04-28 Homing peptide-guided decorin conjugates for use in treating epidermolysis bullosa

Publications (2)

Publication Number Publication Date
CN115605218A CN115605218A (zh) 2023-01-13
CN115605218B true CN115605218B (zh) 2026-03-24

Family

ID=75870661

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180031725.5A Active CN115605218B (zh) 2020-04-28 2021-04-28 用于治疗大疱性表皮松解症的归巢肽引导的核心蛋白聚糖缀合物

Country Status (10)

Country Link
US (1) US20230167162A1 (https=)
EP (1) EP4142771A1 (https=)
JP (1) JP7824885B2 (https=)
KR (1) KR20230005314A (https=)
CN (1) CN115605218B (https=)
AU (1) AU2021266157A1 (https=)
BR (1) BR112022021879A2 (https=)
CA (1) CA3180694A1 (https=)
IL (1) IL297703A (https=)
WO (1) WO2021219940A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118001404B (zh) * 2024-02-06 2025-02-25 四川大学华西医院 抑制C17orf67基因表达试剂在制备治疗获得性大疱表皮松解症药物中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136869A2 (en) 2006-12-06 2008-11-13 Burnham Institute For Medical Research Methods and compositions related to targeting wounds, regenerating tissue, and tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Exposed CendR Domain in Homing Peptide Yields Skin-Targeted Therapeutic in Epidermolysis Bullosa;Toini Pemmari;Molecular Therapy;20200831;第28卷(第8期);全文 *

Also Published As

Publication number Publication date
CN115605218A (zh) 2023-01-13
CA3180694A1 (en) 2021-11-04
BR112022021879A2 (pt) 2022-12-20
JP2023523719A (ja) 2023-06-07
WO2021219940A1 (en) 2021-11-04
AU2021266157A1 (en) 2022-12-08
JP7824885B2 (ja) 2026-03-05
EP4142771A1 (en) 2023-03-08
IL297703A (en) 2022-12-01
US20230167162A1 (en) 2023-06-01
KR20230005314A (ko) 2023-01-09

Similar Documents

Publication Publication Date Title
EP3065765B1 (en) Use of il-22 dimers in manufacture of medicaments for treating pancreatitis
US11224662B2 (en) Methods and therapeutics comprising ligand-targeted ELPs
CN102378635A (zh) 重组人白蛋白-人粒细胞集落刺激因子融合蛋白的新稳定制剂
JP6339231B2 (ja) 線維症性疾患の処置のためのＴｒａｉｌレセプターアゴニスト
US20190247317A1 (en) Icam-1 targeting elps
EP4200319A1 (en) Annexin a1 n-terminal peptide formulations and methods
US20200062811A1 (en) Yap protein inhibiting polypeptide and application thereof
JP2001525337A (ja) 前立腺癌の治療に有効なコンジュゲート
CN109789180A (zh) Kif13b衍生的肽和抑制血管生成的方法
CN115605218B (zh) 用于治疗大疱性表皮松解症的归巢肽引导的核心蛋白聚糖缀合物
CN105228642A (zh) 通过抑制转录因子atf5来抑制肿瘤细胞的组合物和方法
WO2022204331A1 (en) Compositions comprising branched kgf-2 derived peptides and methods for use in ocular treatment
Pemmari et al. Domain in Homing Peptide Yields Skin-Targeted Therapeutic in Epidermolysis Bullosa
HK1223556B (zh) Il-22二聚体在制备用於治疗胰腺炎的药物中的用途
HK1236396A1 (en) Trail receptor agonists for treatment of fibrotic diseases
HK1228418A1 (en) Yap protein inhibiting polypeptide and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant